BridgeMD
Trial of different schemes of PM14 alone and in combination with radiotherapy in soft tissue sarcomas and other solid tumors
EU CTIS ID: 2024-519893-38-00
What this study is testing
COHORTS A (24-h IV PM14 in advanced sarcomas) and B (3-h IV PM14 3 consecutive days in advanced sarcomas) Phase I: To determine the maximum tolerated dose (MTD) of PM14 to be used as recommended phase 2 dose (RP2D). COHORTS E (24-h IV PM14 or 3-h IV PM14 3 consecutive days - Expanded to advanced L-sarcomas) and F (24-h IV PM14 or 3-h IV PM14 3 consecutive days - Expanded to other advanced STS: non L-sarcomas) Phase II: To evaluate the progression-free survival rate (PFSR) at 6 months. COHORT C (Best scheme of PM14 plus RTP (3 Gy x 10 days = 30 Gy) in advanced solid tumors: sarcoma, head and neck, and others) Phase I: To determine the MTD of PM14 to be used as RP2D. Phase II: To evaluate the ORR in irradiated nodules only. This objective is considered as a surrogate of palliative relief. COHORT D (Best scheme of PM14 + RTP (1.8 Gy x 25 days = 45 Gy) in localized intermediate sarcoma) Phase I: To determine the MTD of PM14 to be used as RP2D. Phase II: To evaluate the ORR.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients must voluntarily sign the informed consent before any study test is conducted that is not part of routine patient care. (All cohorts)
- Patients must have a diagnosis of advanced soft tissue sarcoma, or recurrent head & neck suitable for reirradiation or other advanced or metastatic solid tumor not suitable for metastasectomy or surgery resection or not oncologically recommended metastasectomy. A centralized diagnosis will be performed, and the tumor sample must be available and sent prior to PM14 start. For phase II part, only soft tissue sarcomas will be enrolled. (Cohort C).
- Patients must have received a previous chemotherapy line in advanced disease. (Cohort C)
- A centralized diagnosis of sarcoma, which includes: undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma, leiomyosarcoma, sclerosing epithelioid fibrosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumors, sarcoma NOS, fibrosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, epithelioid sarcoma, clear cell sarcoma, dedifferentiated or aggressive features in solitary fibrous tumor, extraskeletal myxoid chondrosarcoma, angiosarcoma, epithelioid hemangioendothelioma, … A centralized diagnosis of DD liposarcoma or myxoid/hypercellular liposarcoma or leiomyosarcoma must be confirmed for patients in cohort E. (Cohorts A, B, E, and F)
- Disease distribution must allow meeting with normal tissue constrains of radiation therapy. Radiation oncologist must confirm this point at local sites. (Cohort C).
- Metastatic spread could be present in several organs (i.e., lungs and pelvic fossa) however, not all the locations have to be irradiated. (Cohort C).
You likely can't join if
- Performance status ≥ 2 (ECOG). (All cohorts)
- Psychological, family, social or geographic circumstances that limit the patients’ ability to comply with the protocol or informed consent. (All cohorts).
- Patients participating in another clinical trial or receiving any other investigational product. (All cohorts).
- Patients who had participated in another clinical trial and/or had received any other investigational product in the last 30 days prior to PM14 start. (All cohorts).
- Prior treatment with lurbinectedin, trabectedin or PM14. (All cohorts).
- Histologies other than those described in the inclusion criteria. (Cohorts A, B, E and F).
See the full eligibility criteria
Who can join
- Patients must voluntarily sign the informed consent before any study test is conducted that is not part of routine patient care. (All cohorts)
- Patients must have a diagnosis of advanced soft tissue sarcoma, or recurrent head & neck suitable for reirradiation or other advanced or metastatic solid tumor not suitable for metastasectomy or surgery resection or not oncologically recommended metastasectomy. A centralized diagnosis will be performed, and the tumor sample must be available and sent prior to PM14 start. For phase II part, only soft tissue sarcomas will be enrolled. (Cohort C).
- Patients must have received a previous chemotherapy line in advanced disease. (Cohort C)
- A centralized diagnosis of sarcoma, which includes: undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma, leiomyosarcoma, sclerosing epithelioid fibrosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumors, sarcoma NOS, fibrosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, epithelioid sarcoma, clear cell sarcoma, dedifferentiated or aggressive features in solitary fibrous tumor, extraskeletal myxoid chondrosarcoma, angiosarcoma, epithelioid hemangioendothelioma, … A centralized diagnosis of DD liposarcoma or myxoid/hypercellular liposarcoma or leiomyosarcoma must be confirmed for patients in cohort E. (Cohorts A, B, E, and F)
- Disease distribution must allow meeting with normal tissue constrains of radiation therapy. Radiation oncologist must confirm this point at local sites. (Cohort C).
- Metastatic spread could be present in several organs (i.e., lungs and pelvic fossa) however, not all the locations have to be irradiated. (Cohort C).
- Those lesions considered for radiation therapy have to be related to symptoms (for phase II). (Cohort C).
- It is allowed that not all the lesions will be under radiation fields. As a general rule, the priority is to select, as target-irradiating lesions, those with greater increase in size and those largest lesions if related to symptoms. Irradiating pulmonary lesions with infiltration of pleural serosa is discouraged. (Cohort C).
- Radiological disease progression must be documented within 6 months prior to study entry. (Cohort C)
- Patients must have been considered eligible for systemic chemotherapy. A maximum of three previous lines in phase I and two previous lines in phase II for advanced/metastatic disease are allowed. (Cohort C).
- The following histological subtypes can be included for the phase II part (central pathology review is mandatory before accrual): undifferentiated pleomorphic sarcoma (UPS), leiomyosarcoma, angiosarcoma, epithelial hemangioendothelioma, liposarcoma and its variants (well differentiated, dedifferentiated, myxoid/round cell, pleomorphic), synovial sarcoma, fibrosarcoma and its variants (epithelial fibrosarcoma/low grade fibromyxoid sarcoma), solitary fibrous tumor, malignant peripheral nerve sheath tumor (MPNST), myxofibrosarcoma, epithelioid sarcoma and (NOS) unclassified sarcoma. (Cohort C)
- Normal cardiac function with a LVEF ≥ 50% by echocardiogram or MUGA. (All cohorts.)
- Patients must have received a previous chemotherapy line in advanced disease unless contraindicated or not indicated. (Cohorts A, B, E, and F)
- Radiological disease progression must be documented within 6 months prior to study entry. (Cohorts A, B, E, and F.)
- The patient must have been considered eligible for systemic chemotherapy. A maximum of two previous lines for advanced/metastatic disease are allowed. (CohortsA, B, E and F.)
- Age: 18-75 years. (All cohorts.)
- Measurable disease according to RECIST v1.1 criteria. (All cohorts)
- Performance status ≤1 (ECOG).
- Men or women of childbearing potential must be using an effective method of contraception before entry into the study and throughout the same and for 3 months (men) and 6 months (women) after ending study treatment. Women of childbearing potential must have a negative serum or urine pregnancy test before study entry. (All cohorts.)
- Patients must have a diagnosis of localized soft tissue sarcoma that lacks one or more of the following risk criteria: G3, deep and > 5 cm. At least G2 is required (i.e., G3, superficial and > 5 cm; or G3 < 5 cm deep; or G2, deep and > 5 cm, etc.). (Cohort D)
- Patients must be diagnosed by core-biopsy and the elapsed time between biopsy and enrollment must be shorter than 6 weeks. (Cohort D)
- Patients must be diagnosed by central pathology review with one of the following subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma, synovial sarcoma, sarcoma NOS, fibrosarcoma, myxoid liposarcoma, dedifferentiated liposarcoma, solitary fibrous tumor (the formerly malignant subtype). (Cohort D)
- HBV and HCV serologies must be performed prior to inclusion. If HbsAg is positive it is recommended to reject the existence of replicative phase (HbaAg+, DNA VHB+). If these were positives the inclusion is not recommended, remaining at investigators' discretion the preventive treatment with lamivudine. If a potential patient is positive for anti-HCV antibodies, presence of the virus should be ruled out with a qualitative PCR, or the patient should NOT be included in the study (if a qualitative PCR cannot be performed then patient will not be able to enter the study). (All cohorts)
- Only sarcomas of limbs or trunk wall will be eligible for this cohort. (Cohort D).
- Disease distribution allows meeting with normal tissue constraints of radiation therapy. Radiation oncologist must confirm this point at local sites. (Cohort D).
- Patients must have resectable primary tumor while it is allowed to enroll patients with metastatic spread that could be potentially resectable. (Cohort D)
- Patients must have criteria of operability for the primary tumor. (Cohort D)
- Patients must have been considered eligible for systemic chemotherapy. (Cohort D).
- Patients have to be candidates for MRI test. (Cohort D).
- Patient must have a central venous catheter for PM14 treatment. (All cohorts)
- Patients must have a diagnosis of soft tissue sarcoma with metastasis, and not suitable for metastasectomy or surgery resection or not oncologically recommended metastasectomy. A centralized diagnosis confirmation will be performed and the tumor sample must be available and sent prior to inclusion to this end. (Cohorts A, B, E, and F: PM14 monotherapy in advanced disease)
- A centralized diagnosis of sarcoma, which includes: undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma, leiomyosarcoma, sclerosing epithelioid fibrosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumors, sarcoma NOS, fibrosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, epithelioid sarcoma, clear cell sarcoma, dedifferentiated or aggressive features in solitary fibrous tumor, extraskeletal myxoid chondrosarcoma, angiosarcoma, epithelioid hemangioendothelioma, well-differentiated/dedifferentiated liposarcoma and myxoid liposarcoma. A centralized diagnosis of DD liposarcoma or myxoid/hypercellular liposarcoma or leiomyosarcoma must be confirmed for patients in cohort E. (Cohorts A, B, E and F)
- Patients must have received a previous chemotherapy line in advanced disease, unless contraindicated or not indicated. (Cohorts A, B, E and F).
- Radiological disease progression must be documented within 6 months prior to study entry. (Cohorts A, B, E and F).
- Patients must have been considered eligible for systemic chemotherapy. A maximum of three previous lines in cohorts A and B and two previous lines in cohorts E and F for advanced/metastatic disease are allowed. (Cohorts A, B, E and F).
What rules you out
- Performance status ≥ 2 (ECOG). (All cohorts)
- Psychological, family, social or geographic circumstances that limit the patients’ ability to comply with the protocol or informed consent. (All cohorts).
- Patients participating in another clinical trial or receiving any other investigational product. (All cohorts).
- Patients who had participated in another clinical trial and/or had received any other investigational product in the last 30 days prior to PM14 start. (All cohorts).
- Prior treatment with lurbinectedin, trabectedin or PM14. (All cohorts).
- Histologies other than those described in the inclusion criteria. (Cohorts A, B, E and F).
- Previous treatment with radiotherapy (except if previous radiotherapy treatment plus planned study radiotherapy treatment allow tissue constrains). (Cohort C).
- Severe COPD or other severe pulmonary diseases. (Cohort C).
- Histologies other than those described in inclusion criteria. (Cohort C).
- High-risk localized patients are not allowed to be enrolled (those G3, deep, and larger than 5 cm or those with at least 40% risk of death by sarculator nomogram). (Cohort D).
- Previous treatment with radiotherapy. (Cohort D)
- Plasma bilirubin > ULN. (All cohorts).
- Primary tumor location other than those indicated in the inclusion criteria. (Cohort D)
- Histological subtypes other than those indicated in the inclusion criteria. (Cohort D).
- Unresectable or inoperable primary tumor. (Cohort D)
- Creatinine > 1.6 mg/dL. (Todas las cohortes).
- History of other cancer with less than 5 years free of disease with the exception of adequately treated basal cell carcinoma or in situ cervical cancer. (All cohorts).
- Patients who do not provide consent for mandatory biological samples cannot participate in the study. (All cohorts).
- Significant cardiovascular disease (for example, dyspnea > 2 NYHA). (All cohorts).
- Significant systemic diseases grade 3 or higher on the NCI-CTCAE v5.0 scale, that limit patient availability, or according to investigator judgment may significantly contribute to treatment toxicity. (All cohorts).
- Uncontrolled bacterial, mycotic or viral infections. (All cohorts).
- Women who are pregnant or breastfeeding. (All cohorts).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.